Relapse of ocular symptoms after remission of myasthenia gravis-A comparison of relapsed and complete remission cases

Clinical Neurology and Neurosurgery

Volumn 105, Issue 2, 2003, Pages 75-77

  Wakata, Nobuo ^a   Iguchi, Hiroaki ^a   Sugimoto, Hideki ^a   Nomoto, Nobuatu ^a   Kurihara, Teruyuki ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Complete remission myasthenia gravis; EOM fiber; Myasthenia gravis; Relapsing myasthenia gravis

Indexed keywords

PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG MEGADOSE; EXTRAOCULAR MUSCLE; EYE DISEASE; FEMALE; HUMAN; MALE; MYASTHENIA GRAVIS; RELAPSE; REMISSION; SYMPTOM; THYMECTOMY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; EYE DISEASES; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PREDNISOLONE; RECURRENCE; THYMECTOMY;

EID: 0037384604     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-8467(02)00104-X     Document Type: Article

References (14)

1. Wakata N. Treatment of myasthenia gravis. Clin. Neurol. (Tokyo). 39:1999;1222-1225.
2. Masaoka A., Monden Y., Nakahara K., Tanioka T. Follow-up study of thymoma with special reference to their clinical stages. Cancer. 48:1981;2485-2492.
3. Wakata N., Fujioka T., Nishina M., Kawamura Y., Kobayashi M., Kinoshita N. Myasthenia gravis and invasive thymoma. A 20-year experience. Eur. Neurol. 33:1993;115-120.
4. Warmolts J.R., Engel W.K., Whitaker J.N. Alternate-day prednisone in a patient with myasthenia gravis. Lancet. II:1972;1198-1199.
5. Gronseth G.S., Barohn R.J. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 55:2000;7-15.
6. Nakazato H., Mizuno Y., Tamaoki M., Tsuchiya M., Yoshimatu H., Satoyoshi E. Prognostic survey of patients with myasthenia gravis after thymectomy. Satoyoshi E. Study of the pathogenesis, treatment and prevention in myasthenia gravis. 1978;183-194 The Ministry of Health and Welfare in Japan from Japanese Government.
7. Wakata N., Nemoto H., Niizuma M., Araki Y., Kinoshita M. Myasthenia gravis and steroid therapy. Clin. Neurol. (Tokyo). 32:1992;131-137.
8. Kaminski H.J., Maas E., Spiegel P., Ruff R.L. Why are eye muscles frequently involved in myasthenia gravis. Neurology. 40:1990;1663-1669.
9. Oda K. Differences in acetylcholine receptor-antibody interactions between extraocular and extremity muscle fibers. Ann. New York Acad. Sci. 681:1993;238-255.
10. Horton R.M., Manfredi A.A., Conti-Tronconi B.M. The 'embryonic' gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle. Neurology. 43:1993;983-986.
11. Daroff R.B. Ocular myasthenia: diagnosis and therapy. Glaser L.J. Neuro-ophthalmology. 1980;62-71 C.V. Mosby, St. Louis.
12. Hudson C.S., Rash J.E., Tiedtand T.N., Alubuquerque E.X. Neostigmine-induced alterations at the mammalian neuromuscular junction. II. Ultrastructure. J. Pharm. Exp. Ther. 205:1978;341-356.
13. Tiedtand T.N., Alubuquerque E.X., Hudson C.S., Rash J.E. Neostigmine-induced alterations at the mammalian neuromuscular junction. I. Muscle contraction and electrophysiology. J. Pharm. Exp. Ther. 205:1978;326-339.
14. Hilton-Brown P., Stalberg E.V., Osterman P.O. Signs of reinnervation in myasthenia gravis. Muscle Nerve. 5:1982;215-221.